Media Releases

Statement to Physician Payments Sunshine Act Final Rule

WASHINGTON, D.C. (February 1, 2013) – Pharmaceutical Research and Manufacturers of America (PhRMA) Senior Vice President Matthew Bennett issued the following statement today: “PhRMA is currently reviewing the final regulation of the Physician Payments Sunshine Act and looks forward to seeing how CMS addressed key concerns that were previously raised. PhRMA remains committed to the principles of the Sunshine Act and continues to believe that careful implementation is essential to ensuring that Sunshine fulfills its objective of usable, transparent, and understandable sharing of information.” About PhRMA The Pharmaceutical Research and Manufacturers of America (PhRMA) represents the country’s leading innovative biopharmaceutical research and biotechnology companies...

Latest Releases

Innovation & Adherence: Two Paths to Better Controlling Diabetes

11/12/2012

Ipsen Biopharmaceuticals and Onyx Pharmaceuticals Join PhRMA as Research Associate Members

America’s biopharmaceutical research companies currently are developing 221 innovative new medicines to help the nearly 26 million patients in the United States affected by diabetes. These medicines in development – all in either clinical trials or under review by the Food and Drug Administration (FDA) – include 32 for type 1 diabetes, 130 for type 2 and 64 for diabetes-related conditions, according to a new report released by the Pharmaceutical Research and Manufacturers of America (PhRMA).

Rotary International and Global Partners Contribute to a Polio-Free India

11/3/2012

Washington, D.C. (November 3, 2012) — The Pharmaceutical Research and Manufacturers of America (PhRMA) and its members are pleased to celebrate one of the most significant global health achievements of the 21st century. For over the past three years, we have supported Rotary International’s PolioPlus program in India through grants and contributions, some of which have been matched by the Bill and Melinda Gates Foundation.

PhRMA Statement on Rx Response’s Pharmacy Status Reporting Tool Activation in 11 States and the District of Columbia

10/31/2012

Pharmaceutical Research and Manufacturers of America (PhRMA) Senior Vice President Matthew Bennett issued the following statement today on Rx Response activation in the wake of Hurricane Sandy:

PDUFA V Sets New Course for Regulatory Science – Joint BIO/PhRMA Statement

10/1/2012

Pharmaceutical Research and Manufacturers of America (PhRMA) President and CEO John J. Castellani and Biotechnology Industry Organization (BIO) President and CEO Jim Greenwood today released the following joint statement on the implementation of the Prescription Drug User Fee Act (PDUFA V):

PhRMA Statement on Avalere Health Analysis on Medicare Part D Premiums

9/25/2012

Pharmaceutical Research and Manufacturers of America (PhRMA) Senior Vice President Matthew Bennett issued the following statement today on findings from Avalere Health on Medicare Part D premiums:

PhRMA Statement on Bloomberg Article

9/19/2012

Pharmaceutical Research and Manufacturers of America (PhRMA) Senior Vice President Matthew Bennett issued the following statement today: “An article published today by Bloomberg does not accurately reflect PhRMA’s position on Medicare Part D or other health care policy issues. The article is based on improperly obtained internal documents that were in draft form. The documents do not contain official PhRMA policy positions, which are set by the organization’s Board of Directors.

Your name
Your email
Recipient email(s) (separated by commas)
Subject

Media Releases

Latest Releases

Subscribe to our Email Updates